Capricor Therapeutics (CAPR) Tops Q2 EPS by 6c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $3.92 million versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• B.Riley Upgrades Capricor Therapeutics (CAPR) to Buy
• Empress Royalty acquires Tongon gold stream for $62M
• The Fed is hiking. Why isn't UBS worried about stocks?